Abstract
Mitoxantrone (MITOX) is an anthracenedione with close resemblance to the anthracyclines and has shown antitumor effect in adult acute leukemia. Clinical data suggest that a) MITOX is not completely cross-resistant with anthracyclines [1,2]; b) The antileukemic activity of MITOX is similar to [3] or even higher [4] than that of anthracyclines and 3) MITOX may be less (cardio-) toxic than anthracyclines [5]. Reports about MITOX in childhood leukemia are restricted to refractory/relapsed patients [6–9]. To determine the possible value of MITOX in childhood acute lymphoblastic leukemia (ALL) at initial diagnosis we performed an in vitro phase II study. A comparison was made between results obtained with MITOX and the anthracyclines DNR and doxorubicin (DOX). We used the short-term, semi-automated MTT assay [10,11].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Sem Oncol 11: 36–40
Hiddeman W, Büchner TH, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gcrith-Stolzenburg S, Donhuijsen-Ant R, Lengfelder E, Hoelzer D (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 4: 637–640
Cuttner J, Mick R, Budman DR, Mayer RJ, Lee EJ, Henderson ES, Weiss RB, Paciucci PA, Sobol R, Davey F, Bloomfield C, Schiffer C (1991) Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: A CALGB Study. Leukemia 5: 425–431
Arlin Z, Case Jr DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K, Lederle Cooperative Group (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4: 177–183
Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571
Graham ML, Estrada J, Ragab AH, Starling KA, Rosen D, Wilkerson RW (1991) Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group Study. Invest New Drugs 9: 263–267
Ritter J, Creutzig U, Henze G, Jürgens H, Bode U, Prindull G, Schellong G (1987) Hochdosiertes Ara-C in Kombination mit Mitoxantron bei der Therapie der AML im Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10: 24–27
Starling KA, Mulne AF, Vats TS, Schoch I, Dukart G (1985) Mitoxantrone in refractory acute leukemia in children: a Phase I study. Invest New Drugs 3: 191–195
Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, Glaubiger DL, Cohen LF (1985) Phase I trial of mitoxantrone in children. Cancer Treatment Rep 69: 403–407
Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP (1990) In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76: 2327–2336
Veerman AJP, Pieters R (1990) Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 74: 381–384
Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64: 469–474
Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338: 399–403
Larson RA, Kaly KM, Choi KE, Han DS, Sinkule JA (1987) A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 5: 391–397
Pieters R, Kaspers GJL, Van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJP (1992) In vitro drug resistance in childhood acute lymphoblastic leukemia in relation to age and immunophenotype. Haematol Blood Transf 34: 309–320
Hammond D, Sather H, Nesbit M, Miller D, Coccia P, Bleyer A, Lukens J, Siegel S (1986) Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14: 124–134
Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, Look AT, Mahoney D, Ragab A, Pullen OJ, Land VJ (1990) Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(l; 19) (q23; p13): a Pediatric Oncology Group Study. Blood 76: 117–122
Van Wering ER, Van ’T Veer MB, Akkerboom JC, Vissers-Praalder EC, Pinkster T, De Waal FC (1986) The significance of the white blood cell count and of immunological typing for the prognosis of acute lymphatic leukaemia in children. Ned Tijdschr Geneeskd 130: 165–169
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kaspers, G.J.J.L. et al. (1994). Antileukemic Activity In Vitro of Mitoxantrone and Anthracyclines in Untreated Childhood Acute Lymphoblastic Leukemia. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_49
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_49
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive